Stocks Health care ABEO
NASDAQ · Health careAbeona Therapeutics Inc. (ABEO)
It posted a net loss of $62.5M. In fiscal 2025 capital spending exceeded operating cash flow by $84.3M. At September 30, 2026 it held $66.3M in cash against $11.8M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Abeona Therapeutics Inc.
- Net worth
- Abeona Therapeutics Inc. has a market value (market cap) of $140.4M at the latest share price, and shareholders' equity of $125.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $76.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Abeona Therapeutics Inc.'s next report is expected around March 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Abeona Therapeutics Inc. does
Abeona Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker ABEO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $5.8M | $71.2M | $1.01 | -$84.3M |
| 2024 | n/a | -$63.7M | -$1.55 | -$58.5M |
| 2023 | $3.5M | -$54.2M | -$2.53 | -$37.3M |
| 2022 | $1.4M | -$39.7M | -$5.53 | -$43.6M |
| 2021 | $3M | -$84.9M | -$0.86 | -$69.8M |
| 2020 | $10M | -$84.2M | -$0.91 | -$36.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where ABEO ranks in Health care
Latest SEC filings
What Abeona Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Quarterly report 10-Q · period to September 30, 2026Revenue was $13.5M; diluted EPS -$0.08 versus -$0.10.
- November 9, 2026
- November 9, 2026
- October 23, 2026Activist stake (5% or more) SCHEDULE 13D
- September 15, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 13, 2026Quarterly report 10-Q · period to June 30, 2026Revenue rose 2,745% to $11.4M versus the same quarter last year; diluted EPS -$0.35 versus $1.71.
- August 13, 2026
- June 26, 2026
- June 12, 2026
Insider trades
What the people running Abeona Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $296.4K worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 29, 2026 | Vasanthavada MadhavChief Commercial Officer | Sold | 4,902 | $25.3K |
| September 29, 2026 | O'Malley Brendan M.SVP, Chief Legal Officer | Sold | 6,727 | $34.7K |
| September 29, 2026 | Vazzano Joseph WalterChief Financial Officer | Sold | 9,191 | $47.4K |
| September 29, 2026 | Seshadri VishwasChief Executive Officer, Director | Sold | 19,608 | $101.1K |
| September 1, 2026 | Alvino MarkDirector | Sold | 15,000 | $88K |
| July 21, 2026 | Vazzano Joseph WalterChief Financial Officer | Sold | 1,478 | $9.7K |
| July 9, 2026 | Vasanthavada MadhavChief Commercial Officer | Sold | 12,606 | $87.8K |
| July 9, 2026 | O'Malley Brendan M.SVP, Chief Legal Officer | Sold | 12,050 | $83.9K |
Who owns ABEO
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Nantahala Capital Management, LLC13G, passive with 2 related filers | 9.99% | May 15, 2026 |
| James Russell Revocable Trust13D, may seek influence with 1 related filers | 6.1% | October 23, 2026 |
| Nantahala Capital Partners Limited Partnership13G, passive | 5.82% | May 15, 2026 |
| Orin Hirschman13G, passive with 1 related filers | 5.4% | April 28, 2026 |
| Funicular Funds, LP13G, passive with 2 related filers | 5.3% | April 6, 2026 |
| Daniel Kaufman13G, passive | 5.16% | March 27, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 127 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Nantahala Capital Management, LLC | 10,272,980 | +5,259,928 |
| BlackRock, Inc. | 3,352,474 | +156,944 |
| Cable Car Capital, LP | 3,007,329 | 0 |
| AIGH Capital Management LLC | 2,987,000 | -113,000 |
| Vanguard Capital Management LLC | 2,211,433 | +46,582 |
| OneDigital Investment Advisors LLC | 1,653,024 | new |
| AWM Investment Company, Inc. | 1,486,130 | +683,000 |
| Geode Capital Management, LLC | 1,261,090 | +51,293 |
| Kennedy Capital Management LLC | 1,240,071 | -23,440 |
| Goldman Sachs Group Inc | 1,224,806 | +94,187 |
| State Street Corp | 1,040,228 | +82,900 |
| Propel Bio Management, LLC | 983,070 | -346,829 |
| Nan Fung Trinity (HK) Ltd | 956,770 | 0 |
| Diametric Capital, LP | 755,021 | +143,501 |
| J. Goldman & Co LP | 678,173 | +37,643 |
| Silverarc Capital Management, LLC | 610,407 | -38,535 |
| Rubric Capital Management LP | 608,771 | new |
| Stonepine Capital Management, LLC | 557,284 | -189,303 |
| Northern Trust Corp | 552,630 | +116,657 |
| Citigroup Inc | 548,300 | +25,855 |
Insiders
13 insiders reported holding 3,537,219 shares in total, about $8.7M at the last price.
| Holder | Shares |
|---|---|
| Seshadri VishwasChief Executive Officer, Director | 1,286,500 |
| Vazzano Joseph WalterChief Financial Officer | 482,888 |
| O'Malley Brendan M.SVP, Chief Legal Officer | 421,226 |
| Vasanthavada MadhavChief Commercial Officer | 285,721 |
| Amoroso MichaelDirector | 217,779 |
| Charles Faith L.Director | 176,407 |
| Wuchterl Donald A.Director | 167,935 |
| Alland LeilaDirector | 162,614 |
| Silverstein Christine BerniDirector | 119,562 |
| Zeiher Bernhardt GDirector | 84,458 |
Questions about ABEO
What does Abeona Therapeutics Inc. do?
Abeona Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as ABEO. Its shares trade on NASDAQ under the ticker ABEO.
What is Abeona Therapeutics Inc.'s net worth?
Abeona Therapeutics Inc. has a market value (market cap) of $140.4M at the latest share price, and shareholders' equity of $125.9M on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Abeona Therapeutics Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $62.5M.
When did Abeona Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Abeona Therapeutics Inc.'s next earnings report?
Abeona Therapeutics Inc.'s next report is expected around March 16, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare ABEO with
Follow ABEO
Get an email when Abeona Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Abeona Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.